GDC-4198
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GDC-4198, covering 2026-04-21 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer [Phase 1, Phase 2]